TrialJournal for immunotherapy of cancer2020

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing.

Danny Rischin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.